Kiniksa Pharmaceuticals International, plc (KNSA)

KNSA Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	423.24	270.26	220.18	38.54	-
Revenue Growth (YoY)	56.61%	22.75%	471.24%	-	-
Cost of Revenue	189.22	89.93	46.97	9.94	-
Gross Profit	234.02	180.33	173.21	28.61	-
Selling, General & Admin	168.01	129.43	97.95	85.95	45.32
Research & Development	111.62	76.1	65.49	99.3	112.04
Operating Expenses	279.63	205.52	163.44	185.25	157.36
Operating Income	-45.62	-25.2	9.77	-156.64	-157.36
Other Non Operating Income (Expenses)	9.46	8.54	1.25	0.1	1.13
Pretax Income	-36.15	-16.65	11.03	-156.54	-156.23
Income Tax Expense	7.04	-30.74	-172.34	1.39	5.15
Net Income	-43.19	14.08	183.36	-157.92	-161.38
Net Income to Common	-43.19	14.08	183.36	-157.92	-161.38
Net Income Growth	-	-92.32%	-	-	-
Shares Outstanding (Basic)	71	70	69	69	62
Shares Outstanding (Diluted)	71	72	70	69	62
Shares Change (YoY)	-0.69%	2.13%	2.69%	10.89%	14.42%
EPS (Basic)	-0.60	0.20	2.64	-2.30	-2.61
EPS (Diluted)	-0.60	0.20	2.60	-2.30	-2.61
EPS Growth	-	-92.31%	-	-	-
Free Cash Flow	25.41	13.17	5.7	-126.71	-136.82
Free Cash Flow Per Share	0.36	0.18	0.08	-1.85	-2.21
Gross Margin	55.29%	66.72%	78.67%	74.22%	-
Operating Margin	-10.78%	-9.32%	4.44%	-406.38%	-
Profit Margin	-10.21%	5.21%	83.28%	-409.72%	-
Free Cash Flow Margin	6.00%	4.87%	2.59%	-328.75%	-
EBITDA	-43.92	-22.86	12.18	-154.28	-154.96
EBITDA Margin	-10.38%	-8.46%	5.53%	-	-
D&A For EBITDA	1.7	2.34	2.4	2.36	2.41
EBIT	-45.62	-25.2	9.77	-156.64	-157.36
EBIT Margin	-10.78%	-9.32%	4.44%	-	-
Revenue as Reported	423.24	270.26	220.18	38.54	-

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q